Hemab Therapeutics Holdings, Inc. Net Fee Amt
Hemab Therapeutics Holdings, Inc. (COAG) had Net Fee Amt of $23.11 thousand as of 2026-05-01, per its S-8 filed 2026-05-04.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-04
- 2026-05-01: Net Fee Amt $23.11K.
- 2026-04-30: Net Fee Amt $5.00K.
- 2026-04-29: Net Fee Amt $9.25K.
- 2026-04-27: Net Fee Amt $19.82K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-01 | $23.11K S-8 · filed 2026-05-04 |
| 2026-04-30 | $5.00K S-1MEF · filed 2026-04-30 |
| 2026-04-29 | $9.25K S-1/A · filed 2026-04-30 |
| 2026-04-27 | $19.82K S-1/A · filed 2026-04-27 |
| 2026-04-08 | $13.81K S-1 · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |